KCNA3 and ischemic stroke: Interestingly, in a study using the middle cerebral artery occlusion model, a model of ischemic stroke that involves the formation of occlusive platelet thrombi in response to combined thrombotic and inflammatory stimuli[71], the selective Kv1.3 blocker Pap-1 dose-dependently reduced the infarct area in rodents, reducing microglial activation and improving neuronal survival[72].